Skip to content

Clinical study of immunomodulation in the treatment of intracerebral hemorrhage

Clinical study of immunomodulation in the treatment of intracerebral hemorrhage

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054251
Enrollment
Unknown
Registered
2021-12-11
Start date
2021-12-20
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracerebral hemorrhage (ICH)

Interventions

control group:Standard management of intracerebral hemorrhage
intervention group:Gormode + standard management

Sponsors

Tianjin Third Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years (non-pregnant), no gender limit; 2. The initial bleeding volume is 5-30ml, and the first symptoms are less than 72 hours after admission; 3. Admission assessment GCS (Glasgow Coma Scale), 6 points and above were selected. In order to limit the variability caused by different bleeding sites, all patients included in the study were bleeding in the basal ganglia.

Exclusion criteria

Exclusion criteria: 1. Difficulty in swallowing, nausea and vomiting of various degrees, and difficulty in taking oral medicines; 2. Blood volume continues to expand, secondary ICH; 3. Existing physical disability (mRS greater than 1 point); 4. Any bradycardia, atrioventricular block; 5. Currently using antitumor drugs, immunosuppressants or immunomodulators; 6. Macular edema.

Design outcomes

Primary

MeasureTime frame
Perihematoma edema;Neurological status;Immune level;

Countries

China

Contacts

Public ContactZhang Jing

Tianjin Third Central Hospital

yadibaby1019@163.com+86 15522242832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026